Trials Sponsors Conditions Drugs Pricing

Conditions

Marginal Zone B Cell Lymphoma

Outcome Measures

Primary Outcomes (1)

clinical characteristics of Marginal zone lymphoma patients
to descrive clinical characteristics of Marginal zone lymphoma patients who were diagnosed and treated in our Hospital.
through study completion, an average of 1 years

Secondary Outcomes (2)

effectiveness
through study completion, an average of 1 years
safety
through study completion, an average of 1 years

Eligibility Criteria

Age18 Years+

Sexall

Healthy VolunteersNo

Age GroupsAdult (18-64), Older Adult (65+)

Sampling MethodNon-Probability Sample

Study Population

Marginal zone lymphoma patients who were diagnosed and treated in our Hospital between December 2012 and December 2018

You may qualify if:

Marginal zone lymphoma patients who were diagnosed and treated in our Hospital between December 2012 and December 2018.

Sponsors & Collaborators

IRCCS Azienda Ospedaliero-Universitaria di Bologna
Otherlead

Study Sites (1)

IRCCS Azienda Ospedaliero - Universitaria di Bologna

Bologna, Bologna, 40138, Italy

RECRUITING

Pier Luigi Zinzani, MDCONTACT+390512143680 pierluigi.zinzani@unibo.it

Alessandro Broccoli, MDCONTACT+39 0512143680 Alessandro.broccoli@studio.unibo.it

MeSH Terms

Conditions

Lymphoma, B-Cell, Marginal Zone

Condition Hierarchy (Ancestors)

Lymphoma, B-CellLymphoma, Non-HodgkinLymphomaNeoplasms by Histologic TypeNeoplasmsLymphoproliferative DisordersLymphatic DiseasesHemic and Lymphatic DiseasesImmunoproliferative DisordersImmune System Diseases

Study Officials

Pier Luigi Zinzani, MD
IRCCS Azienda Ospedaliero-Universitaria di Bologna
PRINCIPAL INVESTIGATOR

Central Study Contacts

Pier Luigi Zinzani, MD

CONTACT

+39 0512143680 pierluigi.zinzani@unibo.it

Alessandro Broccoli, MD

CONTACT

+39 0512143680

Study Design

Study Type: observational
Observational Model: COHORT
Time Perspective: RETROSPECTIVE
Sponsor Type: OTHER
Responsible Party: SPONSOR

Study Record Dates

First Submitted

December 3, 2024

First Posted

February 4, 2025

Study Start

May 2025

Estimated (date passed)

This estimate has passed. The registry has not confirmed an actual date for this milestone.

Primary Completion

October 2025

Estimated (date passed)

Study to Assess Clinical Characteristics and Outcome of Patients with Marginal Zone Lymphomas

Brief Summary

Registry Overview

Trial Relationships

Study Timeline

First Submitted

First Posted

Study Start

Primary Completion

Study Completion

Conditions

Outcome Measures

Primary Outcomes (1)

Secondary Outcomes (2)

Eligibility Criteria

You may qualify if:

Sponsors & Collaborators

Study Sites (1)

MeSH Terms

Conditions

Condition Hierarchy (Ancestors)

Study Officials

Central Study Contacts

Study Design

Study Record Dates

You may not qualify if:

Data Sharing

Source record

Locations

Brief Summary

Registry Overview

Trial Relationships

Related Scientific Literature

Study Timeline

First Submitted

First Posted

Study Start

Primary Completion

Study Completion

Conditions

Outcome Measures

Primary Outcomes (1)

Secondary Outcomes (2)

Eligibility Criteria

You may qualify if:

Sponsors & Collaborators

Study Sites (1)

MeSH Terms

Conditions

Condition Hierarchy (Ancestors)

Study Officials

Central Study Contacts

Study Design

Study Record Dates

You may not qualify if:

Data Sharing

Source record

Locations